CCL5 Molekülinformation
Molecule Name
C-C motif chemokine 5
Molekülalias
EoCP,Eosinophil chemotactic cytokine,SIS-delta,Small-inducible cytokine A5,T cell-specific protein P228,TCP228,D17S136E, SCYA5,CCL5,C-C motif chemokine 5
T-cell-specific protein RANTES
Drug Development Progress
Anzahl der klinischen Arzneimittel2
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
Beta-Chemokine RANTES，Regulated Upon Activation， Normally T-Expressed， And Presumably Secreted，RANTES，TCP228，SIS-Delta，SISd，Small-Inducible Cytokine A5，D17S136E，T Cell-Specific Protein P228，EoCP，C-C Motif Chemokine 5，C-C Motif Chemokine Ligand 5，CCL5，Small Inducible Cytokine A5 (RANTES)，Chemokine (C-C Motif) Ligand 5，T-Cell Specific RANTES Protein，T-Cell Specific Protein P288，Small Inducible Cytokine Subfamily A (Cys-Cys)， Member 5，Eosinophil Chemotactic Cytokine，T-Cell-Specific Protein RANTES，SCYA5，Chemokine CXCL5，MGC17164
Molekülhintergrund
C-C chemokine ligand 5 (CCL5), also known as RANTES, is a target gene of NF-kappaB, and is expressed by T lymphocytes, macrophages, platelets, synovial fibroblasts, tubular epithelium, and certain types of tumour cells. CCL5 plays a role in recruiting a variety of leukocytes into inflammatory sites including T cells, macrophages, eosinophils, and basophils. CCL5 activity is mediated through its binding to CCR1, CCR3, and mainly CCR5.
CCL5 Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| AFX-5931 | AFX-5931 | Phase 2 Clinical | Afecta Pharmaceuticals Inc | Eczema | Details |
| MW-151 | MW01-9-034WH; MW-151; MW01-2-151SRM | Phase 1 Clinical | University Of Kentucky | Drug-Related Side Effects and Adverse Reactions; Poisoning | Details |